Introduction: An intravenous fluid shortage in 2017 prompted health systems to conserve small volume fluids. One strategy to minimize utilization included administering antibiotics as intravenous push (IVP). Pharmacokinetic studies have compared the two administration strategies but a paucity of data exists regarding the clinical efficacy of IVP administration of beta-lactams. The purpose of this study is to compare the clinical efficacy of IVP versus IVPB administration of beta-lactams for the treatment of gram-negative bacteremia. Methods: This retrospective study included adult patients that received aztreonam, cefepime, ceftriaxone, or meropenem for empiric treatment of gram-negative bacteremia between January 1, 2016 and September 15, 2021. The primary outcome was clinical cure at 7 days or discharge, whichever occurred first. Clinical cure was defined as being alive, afebrile, and having an improved or stable SOFA score. Secondary outcomes included the rate of negative repeat blood cultures (if drawn), in-hospital mortality up to 30 days, and hospital and ICU length of stay (LOS). Results: This study included 227 patients were included of which 141 patients received IVP administration and 86 received IVPB administration. The majority of the patients had an E. coli bacteremia (60.8%) from a urinary source (74%). Clinical cure was achieved in 121 (85.8%) of the IVP patients and 77 (89.5%) of the IVPB patients (p=0.415). Repeat cultures were drawn in 44.7% of the IVP group and 53.5% of the IVPB group in which 100% and 97.8%, respectively, were negative (p=0.239). In-hospital mortality (2.1 vs 1.2%, p=0.591), hospital LOS (6.5 vs 6.3 days, p=0.741), and ICU LOS (3.2 vs 3.3 days, p=0.951) were not different between groups. Conclusions: We found no difference in rate of clinical cure between IVPB and IVP Intravenous push administration of beta-lactams. The study sample size may limit broad application of these findings and larger studies are warranted.